» Articles » PMID: 33590936

Genetic and Epigenetic Factors Associated with Increased Severity of Covid-19

Overview
Journal Cell Biol Int
Specialty Cell Biology
Date 2021 Feb 16
PMID 33590936
Citations 35
Authors
Affiliations
Soon will be listed here.
Abstract

Since December 2019, a new form of severe acute respiratory syndrome (SARS) from a novel strain of coronavirus (SARS coronavirus 2 [SARS-CoV-2]) has been spreading worldwide. The disease caused by SARS-CoV-2 was named Covid-19 and declared as a pandemic by the World Health Organization in March 2020. Clinical symptoms of Covid-19 range from common cold to more severe disease defined as pneumonia, hypoxia, and severe respiratory distress. In the next stage, disease can become more critical with respiratory failure, sepsis, septic shock, and/or multiorgan failure. Outcomes of Covid-19 indicate large gaps between the male-female and the young-elder groups. Several theories have been proposed to explain variations, such as gender, age, comorbidity, and genetic factors. It is likely that mixture of genetic and nongenetic factors interplays between virus and host genetics and determines the severity of disease outcome. In this review, we aimed to summarize current literature in terms of potential host genetic and epigenetic factors that associated with increased severity of Covid-19. Several studies indicated that the genetic variants of the SARS-CoV-2 entry mechanism-related (angiotensin-converting enzymes, transmembrane serine protease-2, furin) and host innate immune response-related genes (interferons [IFNs], interleukins, toll-like receptors), and human leukocyte antigen, ABO, 3p21.31, and 9q34.2 loci are critical host determinants related to Covid-19 severity. Epigenetic mechanisms also affect Covid-19 outcomes by regulating IFN signaling, angiotensin-converting enzyme-2, and immunity-related genes that particularly escape from X chromosome inactivation. Enhanced understanding of host genetic and epigenetic factors and viral interactions of SARS-CoV-2 is critical for improved prognostic tools and innovative therapeutics.

Citing Articles

High nasopharyngeal and serum IL-6 levels and the - 573G > C polymorphism (rs1800796) are linked with the risk of severe COVID-19 in a Mexican population: a case‒control study.

Torres-Poveda K, Bahena-Roman M, Contreras-Ochoa C, Lagunas-Martinez A, Bermudez-Morales V, Pando-Robles V BMC Infect Dis. 2025; 25(1):315.

PMID: 40045221 PMC: 11884130. DOI: 10.1186/s12879-025-10695-y.


Micro-Epigenetic Markers in Viral Genome: SARS-CoV-2 Infection Impact on Host Cell MicroRNA Landscape.

Chrysovergis A, Papanikolaou V, Roukas D, Spyropoulou D, Mastronikoli S, Papouliakos S Maedica (Bucur). 2025; 19(4):842-847.

PMID: 39974441 PMC: 11834827. DOI: 10.26574/maedica.2024.19.4.842.


Association of plasma microRNAs with COVID-19 severity and outcome.

Salem S, Lotfy R, Eltaweel N, Elbadry M J Genet Eng Biotechnol. 2024; 22(4):100433.

PMID: 39674647 PMC: 11609541. DOI: 10.1016/j.jgeb.2024.100433.


Infection Inhibits the Efficacy of RBD Protein of SARS-CoV-2 Vaccination via Regulating Humoral and Cellular Immunity.

Zhu F, Zheng W, Gong Y, Zhang J, Yu Y, Zhang J Vaccines (Basel). 2024; 12(7).

PMID: 39066367 PMC: 11281533. DOI: 10.3390/vaccines12070729.


TYK2, IFITM3, IFNAR2 and OAS3 single-nucleotide polymorphisms among severe COVID-19 ICU patients in Morocco.

Benmansour R, Tagajdid M, El Hamzaoui H, Fjouji S, Doghmi N, Houba A Int J Immunopathol Pharmacol. 2024; 38:3946320241257241.

PMID: 38760017 PMC: 11102656. DOI: 10.1177/03946320241257241.


References
1.
Chen J, Jiang Q, Xia X, Liu K, Yu Z, Tao W . Individual variation of the SARS-CoV-2 receptor ACE2 gene expression and regulation. Aging Cell. 2020; 19(7). PMC: 7323071. DOI: 10.1111/acel.13168. View

2.
Paniri A, Hosseini M, Akhavan-Niaki H . First comprehensive computational analysis of functional consequences of SNPs in susceptibility to SARS-CoV-2 among different populations. J Biomol Struct Dyn. 2020; 39(10):3576-3593. PMC: 7284145. DOI: 10.1080/07391102.2020.1767690. View

3.
Verdecchia P, Cavallini C, Spanevello A, Angeli F . The pivotal link between ACE2 deficiency and SARS-CoV-2 infection. Eur J Intern Med. 2020; 76:14-20. PMC: 7167588. DOI: 10.1016/j.ejim.2020.04.037. View

4.
Ayaz S, Crea F . Targeting SARS-CoV-2 using polycomb inhibitors as antiviral agents. Epigenomics. 2020; 12(10):811-812. PMC: 7491010. DOI: 10.2217/epi-2020-0154. View

5.
Tukiainen T, Villani A, Yen A, Rivas M, Marshall J, Satija R . Landscape of X chromosome inactivation across human tissues. Nature. 2017; 550(7675):244-248. PMC: 5685192. DOI: 10.1038/nature24265. View